NeoGenomics (NEO) Reports In-Line Q4 EPS, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
NeoGenomics Reports 40% Revenue Growth to $107 Million in the Fourth Quarter
February 27, 2020 7:10 AM ESTFourth-Quarter 2019 Highlights:
Consolidated revenue increased 39.7% to $106.9 millionClinical Services revenue increased 41.7% to $93.4 million Pharma Services revenue increased 27.5% to $13.5 millionPharma Services backlog increased 31.8% to $130.3 millionCompany issues 2020 financial guidanceFT. MYERS, FL / ACCESSWIRE / February 27, 2020 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced fourth-quarter and full-year 2019 results for the period ended December 31, 2019.
"Our fourth quarter performance concludes a very successful year for NeoGenomics in which our company grew by nearly 50%... More
